These findings strongly implicated that miR-486 may regulate the production of VLDL by controlling the expression of the PTEN, FoxO1a, and MTTP proteins, and suggested a potential theraputic strategy for dyslipidemia. The gene discussed is MT-TP; the disease is metabolic syndrome.